Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Small molecule inhibitors of PARP1/2 such as olaparib have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations. Indeed, in clinical trials PARP1/2 inhibitors elicit sustained anti-tumor responses in patients with germ-line BRCA gene mutations. In hyp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Main Authors: Bajrami, Ilirjana, Frankum, Jessica R., Konde, Asha, Miller, Rowan E., Rehman, Farah L., Brough, Rachel, Campbell, James, Sims, David, Rafiq, Rumana, Hooper, Sean, Chen, Lina, Kozarewa, Iwanka, Assiotis, Ioannis, Fenwick, Kerry, Natrajan, Rachael, Lord, Christopher J., Ashworth, Alan
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886090/
https://ncbi.nlm.nih.gov/pubmed/24240700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2541
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares